[1]罗虎,宫亮,陈永峰,等.CIK维持治疗中晚期肺癌的临床观察及影响因素分析[J].陆军军医大学学报(原第三军医大学学报),2013,35(06):569-572.
 Luo Hu,Gong Liang,Chen Yongfeng,et al.Clinical observation and influencing factors of CIKs in treatment of patients with advanced lung cancer[J].J Amry Med Univ (J Third Mil Med Univ),2013,35(06):569-572.
点击复制

CIK维持治疗中晚期肺癌的临床观察及影响因素分析(/HTML )
分享到:

陆军军医大学学报(原第三军医大学学报)[ISSN:1000-5404/CN:51-1095/R]

卷:
35卷
期数:
2013年第06期
页码:
569-572
栏目:
论著
出版日期:
2013-03-30

文章信息/Info

Title:
Clinical observation and influencing factors of CIKs in treatment of patients with advanced lung cancer
作者:
罗虎宫亮陈永峰祝冰晶周向东杨智余时沧王丹妮
第三军医大学西南医院:呼吸内科,生物治疗中心,检验科
Author(s):
Luo Hu Gong Liang Chen Yongfeng Zhu Bingjing Zhou Xiangdong Yang Zhi Yu Shicang Wang Danni
Department of Respiratory Diseases; Center of Biotherapy; Department of Laboratory Medicine,  Southwest Hospital, Third Military Medical University, Chongqing, 400038, China
关键词:
CIK肺癌免疫系统疗效影响因素安全性
Keywords:
CIK lung cancer immune system effectiveness influencing factor safety
分类号:
R734.2;R730.51
文献标志码:
A
摘要:
目的      分析细胞因子诱导的杀伤细胞(cytokine-induced killer cells,CIK)作为维持治疗手段治疗晚期肺癌患者前后免疫系统变化情况,评估CIK细胞治疗晚期肺癌的有效性并分析其影响因素,对其安全性做初步评估。      方法        选取42例中晚期肺癌患者,并根据性别、年龄、病理类型选择同期行最佳支持治疗的38例患者作为对照组。统计分析应用CIK细胞治疗前后免疫学指标(T细胞亚群、免疫球蛋白等)变化特点,评估其治疗的近期疗效(有效率、控制率),并分析影响CIK治疗效果的因素,比较患者在治疗前后的生活质量变化(KPS评分),观察细胞治疗的安全性。      结果        相比非肺癌患者而言,肺癌患者CD3+、CD4+及CD8+T细胞比例均显著降低(P<0.05);CIK细胞治疗后,CD3+、CD4+ T细胞及CD4+/CD8+比例较治疗前显著提高(P<0.05),而血液中的免疫球蛋白(IgA、IgG、IgM)及肿瘤标志物CEA均无明显改变(P>0.05)。CIK治疗组有效率及疾病控制率分别为42.9%和83.3%,均显著高于对照组的7.9%及55.3% (P<0.05) ;肿瘤分期、是否合并重要脏器转移及KPS评分都是影响CIK治疗效果的因素(P<0.05),而性别、年龄、病理类型则对CIK治疗效果无明显影响(P>0.05);CIK治疗前后KPS评分改善差异有统计学意义(P=0.001),而对照组KPS评分无明显改善(P=0.191);CIK治疗组中4例患者出现一过性的发热或寒战外,未见明显毒副作用。      结论        CIK细胞作为维持治疗手段,可改善肺癌患者免疫失衡,提高有效率和疾病控制率,并在一定程度上改善患者的生活质量且无明显毒副作用。
Abstract:
Objective        To analyze the changes of immune system after cytokine-induced killer cells (CIKs) as maintenance therapy in treatment of patients with advanced lung cancer, to assess the effectiveness and safety of CIKs treatment, and to find out the factors that may influence the efficacy.       Methods        Forty-two patients with advanced lung cancer (stage Ⅲ to Ⅳ) admitted to the First Affiliated Hospital of Third Military Medical University in Chongqing from July 2011 to July 2012 and treated with CIKs were enrolled as a CIKs group, and another 38 advanced lung cancer patients treated with optimal supportive care during the same period were enrolled as a control group. The changes of immune system (including subsets of T cells, immunoglobulin A, immunoglobulin G and immunoglobulin M), therapeutic effects (response rate and disease control rate), quality of life (KPS score), and side effects were compared between the two groups. Furthermore, the factors that might influence the efficacy of CIKs therapy were evaluated.       Results        Compared with people without lung cancer, the ratios of CD3+, CD4+ and CD8+ T cells significantly decreased (P<0.05) in lung cancer patients. After CIKs treatment, the ratios of CD3+ and CD4+ T cells and CD4+/CD8+ significantly increased (P<0.05), while there was no significant change in CD8+ T cells, immunoglobulin A, immunoglobulin G, immunoglobulin M and cancer embryo antigen (CEA) (P>0.05). The response rate (RR) and disease control rate (DCR) were 42.9% and 83.3% in the CIKs group, which were significantly higher than those in the control group (7.9% and 55.3%). Tumor staging, metastasis in vital organs and KPS score were influencing factors for the effectiveness of CIKs treatment (P<0.05), while sex, age and pathological type had no significant effect (P>0.05). KPS score significantly increased in the CIKs group (P=0.001), while no obvious change was observed in the control group (P=0.191). Four patients suffered from transient fever or chills in the process of CIKs transfusion, and no other side effect was observed.       Conclusion        CIKs treatment, as a maintenance therapy, is safe and effective for advanced lung cancer patients, and can also improve the immune imbalance, RR, DCR and quality of life of the patients.

相似文献/References:

[1]谢燕,喻秀丽,童立纺.硼替佐米对A549细胞增殖及p21、p27表达的影响[J].陆军军医大学学报(原第三军医大学学报),2012,34(17):1775.
 Xie Yan,Yu Xiuli,Tong Lifang.Anti-proliferation effect of proteasome inhibitor bortezomib in human lung adenocarcinoma A549 cells[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(06):1775.
[2]王孟昭,张紫萱.肺癌的靶向治疗[J].陆军军医大学学报(原第三军医大学学报),2012,34(20):2035.
 Wang Mengzhao,Zhang Zixuan.Target therapy in lung cancer[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(06):2035.
[3]莫贵艳,李敏,胡成平,等.茶氨酸对内皮细胞生长及肺癌血管生成的影响[J].陆军军医大学学报(原第三军医大学学报),2012,34(20):2043.
 Mo Guiyan,Li Min,Hu Chengping,et al.Theanine suppresses angiogenesis of endothelial cells in vitro and in vivo[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(06):2043.
[4]刘晓丽,马礼鸿,王全义,等.XIAP、c-jun在肺癌组织中的表达及其意义[J].陆军军医大学学报(原第三军医大学学报),2012,34(23):2408.
 Liu Xiaoli,Ma Lihong,Wang Quanyi,et al.Expression and clinical significance of XIAP and c-jun in human lung cancer tissues[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(06):2408.
[5]李长毅,张明川,梅同华,等.持续小剂量化疗对A549肺癌PTEN基因和凋亡的影响[J].陆军军医大学学报(原第三军医大学学报),2007,29(18):1760.
 LI Chang-yi,ZHANG Ming-chuan,MEI Tong-hua,et al.Low-dose metronomic chemotherapy upregulates PTEN and induces apoptosis of A549 pulmonary adenocarcinoma in athymic mice[J].J Amry Med Univ (J Third Mil Med Univ),2007,29(06):1760.
[6]邓丽平,董文,杜艳萍,等.支气管肺泡灌洗液和血清肿瘤标志物联合检测在肺癌诊断中的价值[J].陆军军医大学学报(原第三军医大学学报),2008,30(01):78.
 DENG Li-ping,DONG Wen,DU Yan-ping,et al.Combined determination of tumor markers in serum and bronchoalveolar lavage fluid for lung cancer diagnosis[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(06):78.
[7]李代蓉,周清华,郭占林,等.CYP2E1基因多态性与肺癌遗传易感性的关系[J].陆军军医大学学报(原第三军医大学学报),2008,30(13):1231.
 LI Dai-rong,ZHOU Qing-hua,GUO Zhan-lin,et al.Association between genetic polymorphisms of CYP2E1 and lung cancer susceptibility: a case control study[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(06):1231.
[8]李宁,候丽娟.自体CIK细胞治疗肝癌患者的护理[J].陆军军医大学学报(原第三军医大学学报),2006,28(05):485.
[9]李艳秋,李建春,关洪全,等.肺癌患者外周血Th1/Th2细胞因子及IL-18水平变化与肿瘤分期的关系[J].陆军军医大学学报(原第三军医大学学报),2007,29(08):731.
 LI Yan-qiu,LI Jian-chun,GUAN Hong-quan,et al.Changes of IL-18 and Th1/Th2 in serum of lung cancer patients and their relationship with tumor staging[J].J Amry Med Univ (J Third Mil Med Univ),2007,29(06):731.
[10]戴纪刚,肖颖彬,闵家新,等.非小细胞肺癌线粒体基因组大片段缺失突变研究[J].陆军军医大学学报(原第三军医大学学报),2006,28(21):2123.

更新日期/Last Update: 2013-03-19